R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Oncology - Small molecules (100)

Modality Indication Targets Stage Company Project No. Detail
1 Development of a Lead Compound Targeting RNA Methyltransferase METTL3 for Cancer Immunotherapy
Small molecules Solid tumor (CRC) METTL3 Lead K-MEDI hub RS-2026-25503723
2 Nonclinical Safety and Efficacy Validation of a Novel Photosensitizer (MPP100) for the Treatment of Cervical Dysplasia and Approval of an Investigational New Drug (IND) Application
Small molecules Cervical intraepithelial neoplasia (CIN1-3) & HPV infection HPV-infected dysplastic and hyper-proliferative squamous cells within CIN lesions. Overexpressed LDL Preclinical Dr. inB Inc. RS-2026-25503500
3 Development of Orally Available Small-Molecule Hit and Lead Compounds for Immuno-Oncology via Inhibition of the CD73-Adenosine Axis and Enhancement of Antitumor Immune Activation
Small molecules Immune checkpoint inhibitor-resistant cancers CD73 Hit Gwangju Institute of Science and Technology RS-2026-25502995
4 Preclinical Development of an Oral Small-Molecule PD-L1 Immune Checkpoint Inhibitor for Cancer Therapy
Small molecules Solid tumor PD-L1 Preclinical ILAb Co. Ltd., RS-2026-25502303
5 Discovery of Next-Generation Menin Inhibitor/Degrader Lead Compounds to Overcome Acquired Resistance Mutations
Small molecules AML Menin Lead CoBX Bio., Ltd. RS-2026-25501934
6 Development of Next-Generation Cancer Therapeutics for the Inhibition of Pan-RAS Mutant Signaling
Small molecules CRC ACK1/GCK Preclinical MagicBullet Therapeutics RS-2026-25501930
7 Pre-clinical development of JSC-441, a pan-KRAS inhibitor with KRAS-SOS1 interaction inhibition mechanism
Small molecules KRAS mutated cancers (NSCLC, CRC, PDAC) SOS1 Preclinical Jeil Pharmaceutical RS-2025-25455195
8 Preclinical Study for the Esophageal Cancer Treatment Technology Using the Mechanism of Cancer Cell-Selective Photodynamic Therapy with Next-Generation Photosensitizer HL270
Small molecules Esophageal cancer Photodynamic therapy Preclinical HANLIM PHARM.CO.,LTD RS-2025-25454976
9 Autophagy Inhibition-Based ULK1 Lead Discovery for Dual Targeting of Cancer Cells and TME in Pancreatic Cancer Therapy
Small molecules PDAC ULK1 Lead Cowellbiodigm RS-2025-25454972
10 Discovery of anticancer candidate targeting peroxiredoxin 2-deficient Triple-Negative Breast Cancer for personalized treatment
Small molecules TNBC PRDX2 Candidate VasThera Co., Ltd. RS-2025-25454944
11 Discovery of first-in-class small molecule ***** inhibitors for treatment of RCC
Small molecules RCC ***** Hit Sogang University RS-2025-25452008
12 Clinical research for the development of MASTL inhibitors as a new anti-cancer drug
Small molecules CRC, GC,Sarcoma, TNBC, AML etc. MASTL Phase 1 Avelos Therapeutics, Inc. RS-2025-25446915
13 Research on discovery of lead compounds to develop oral refractory cancer treatment targeting PTM(Post-translational modification) inhibition mechanism
Small molecules AML NMT Lead INNOVO Therapeutics RS-2025-25444455
14 Development of a Neuroendocrine Prostate Cancer Therapy by Targeting NF-κB Signaling via Neddylation inhibition
Small molecules Prostate cancer NEDD8 Lead Korea Research Institute of Chemical Technology RS-2025-02223190
15 Development of novel small molecule anticancer drugs targeting USP1
Small molecules TNBC, Ovarian cancer (BRCA mut) USP1 Candidate HYUNDAI PHARM RS-2025-02223126
16 Development of a second-generation c-MET inhibitor to overcome acquired resistance to first-generation c-MET inhibitors
Small molecules NSCLC cMET Candidate CMG Pharmaceutical Co.Ltd RS-2025-02213745
17 Development of the novel HER2 TKI YH42946 for Solid Tumors
Small molecules NSCLC HER2 Phase 1 YUHAN RS-2025-02213533
18 Preclinical research and development of AD0126 as a selective USP1 inhibitor
Small molecules HRD (+) cancer (TNBC, Ovarian cancer), HRP solid cancer (NSCLC) USP1 Candidate Avelos Therapeutics, Inc. RS-2025-02213433
19 First-in-class pancreatic cancer therapy targeting both tumor metabolism and fibrosis for enhanced efficacy
Small molecules Pancreatic cancer NUAK1 Lead Korea Institute of Radiological and Medical Sciences RS-2025-02213330
20 DWP223: A Selective DNA Polymerase Theta Inhibitor
Small molecules BRCA mutated solid cancer POLQ Preclinical Daewoong Pharmaceutical RS-2025-02213327
21 Phase 2 Clinical Trial of Poseltinib for the Treatment of Relapsed/ Refractory Primary Central Nervous System Lymphoma
Small molecules PCNSL BTK, TEC Phase 2 NOBO Medicine, Inc. RS-2025-02212979
22 Clinical Development of Next-Generation EGFR Mutant Non-Small Cell Lung Cancer Treatment, JIN-A02
Small molecules NSCLC EGFR Phase 1 J INTS BIO RS-2025-02183074
23 Development of pan-KRAS Inhibitor Candidates for KRAS-Mutant Cancer Patients
Small molecules KRAS (+) solid cancer KRAS Candidate Idience Co., Ltd. RS-2025-02183021
24 Global Phase 1 Clinical Development of SNB-101, a Novel Therapeutic for Small Cell Lung Cancer
Small molecules SCLC Topoisomerase 1 Phase 1 SN BioScience Inc. RS-2025-02073050
25 Development of treatment for drug-resistant cancer patients at the stage 4
Small molecules lung cancer, Colon cancer APE1 Hit KAIST RS-2024-00463605
26 Recurring and metastatic colorectal cancer New drug-targeted biomarker HSPA1L-METTL21A Protein-Protein Interactions (PPIs) Development of a New Lead
Small molecules Metastatic colorectal cancer N/A Hit Chosun University School of Medicine RS-2024-00463393
27 Identification of a CDK7 inhibitor as a development candidate for HR+ HER2- metastatic breast cancer patients with resistance to CDK4/6 inhibitors
Small molecules Breast cancer (HR+ HER2-) CDK7 Candidate Cyrus Therapeutics RS-2024-00463231
28 Development of DWP216, a TEAD1 selective inhibitor for NF2 mutant solid cancer patients
Small molecules Solid cancer (NF2 mutant, EGFR mutant, KRAS mutant) TEAD1 Preclinical Daewoong Pharmaceutical Co., LTD RS-2024-00462280
29 Discovery of SHMT2 inhibitors for the treatment of anaplastic thyroid cancers
Small molecules Anaplastic Thyroid Cancer SHMT2 (serine hyroxymethyltransferase 2) Hit Korea Research Institute of Chemical Technology RS-2024-00460989
30 DM5167 Phase 1 Clinical Trial of a 2nd Generation PARP-1 Selective Inhibitor
Small molecules Solid cancer PARP-1 Phase 1 Digmbio RS-2024-00460284
31 A Study on the Development of USP1 inhibitor candidate as a New Synthetic Lethality Target for the Treatment of BRCA (-) and HRD (+) Cancer
Small molecules Cancer (BRCA Mutant) USP1 Candidate AIGEN Sciences RS-2024-00338363
32 Development of novel chemical immune checkpoint inhibitors by targeting CMTM6/PD-L1 axis in the tumor immune microenvironment for lung cancer immunotherapy
Small molecules Lung cancer, Solid cancer CMTM6 Lead Kangwon National University RS-2024-00338105
33 Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy
Small molecules Glioblastoma, Liver cancer WNK3 Hit Checkmate Therapeutics Inc. RS-2024-00337810
34 Discovery of Small-Molecule Immunotherapeutics Dual-Targeting TAM and Treg in the Tumor Microenvironment
Small molecules Cancers(NSCLC, melanoma) with high tumor mutational burden CSF1R, PI3Kδ Lead Chung-Ang University/College of Pharmacy RS-2024-00337284
35 The development of MAST3 inhibitor for anticancer drug
Small molecules Gastric cancer, Colon cancer MAST3 Hit Korea Reserch Institute Of Chemical Technology(KRICT) RS-2024-00336646
36 Completion of CMC, GLP-tox Testing, Clinical Trial Medication Production, and IND Approval for Orally Administerable CD39 Target Inhibitor Preclinical Candidate Substance
Small molecules Colorectal cancer CD39 Preclinical SCBIO Inc. RS-2024-00336376
37 Development of a selective Discoidin Domain Receptor 1 (DDR1) inhibitor with first-in-class novel targets in multiple KRAS G12X-mutant malignant lung and pancreatic cancers
Small molecules KRAS G12X-mutant cancer DDR1 Lead CUREVERSE INC. RS-2024-00336018
38 Discovery of selective first-in-class hit and lead compound targeting novel anti-cancer target SLC1A5_var against malignant tumor
Small molecules incurable cancer SLC1A5_var Hit Yonsei University RS-2024-00334337
39 Development of the candidate for Standard Treatment-Resistant/Refractory Prostate Cancer through direct inhibition of XBP1s, a Mediator of ER stress
Small molecules Metastatic Castration Resistant Prostate Cancer XBP1s Candidate JW C&C Research Laboratories RS-2024-00333115
40 Development of first-in-class small molecule inhibitor targeting novel transcriptional regulator for cancer immunotherapy
Small molecules Solid tumor(ovarian, colorectal, melanoma, etc.) Novel transcriptional regulator function in both cancer and immune cells Lead SAMJIN PHARM.CO.,LTD. RS-2024-00332412
41 Phase 1 clinical study of FB849, HPK1 inhibitor as a nextgeneration immuno-oncology therapy
Small molecules Ovarian cancer, Endometrial cancer, Renal cell carcinoma HPK1 Phase 1 1ST Biotherapeutics, Inc. RS-2024-00332279
42 Global phase 2 studies of precision medicine based c.MET inhibitor ABN401
Small molecules Solid tumor, NSCLC c.MET Phase 2 Abion Inc. RS-2023-00284103
43 Identification of small molecule PKMYT1 inhibitor candidates for development of advanced solid tumor treatment
Small molecules Solid tumor PKMYT1 Candidate Voronoi Inc. RS-2023-00283890
44 Development of SIRT7 inhibitors for the treatment of unresectable hepatocellular carcinoma
Small molecules Cancer SIRT7 Lead Korea Reserch Institute Of Chemical Technology(KRICT) RS-2023-00283539
45 A Study on the Development of First.in.class Myc Inhibitor Candidate for the Treatment of Solid Tumor and Hematologic Cancer
Small molecules Cancer Myc Candidate Incurix Co., Ltd. RS-2023-00283511
46 Non.clinical development of C2.558, a SOS1 inhibitor, for the treatment of patients with KRAS mutant solid tumors
Small molecules Solid tumor KRAS.SOS1 PPI Preclinical Cyrus Therapeutics Inc. RS-2023-00283208
47 Phase 1 clinical Study of ENPP1 inhibitory Immunotherapy TXN10128
Small molecules Solid tumor ENPP1 Phase 1 Txinno Bioscience Inc. RS-2023-00282830
48 Development of an NMC Therapeutic Candidate Using a BRD4.NUT Degrader
Small molecules NUT Midline Carcinoma BRD4.NUT Candidate Innocure Therapeutics Inc. RS-2023-00282701
49 Development of novel small molecule anticancer drugs targeting SMARCA2
Small molecules NSCLC, Melanoma SMARCA2/4 Candidate Hyundai Pharm RS-2023-00259457
50 Development of third-generation antibody-drug conjugate linker technology capable of site-selectively conjugating payloads without antibody modification
Small molecules Gastric/GEJ AbClickⓇPro Lead AbTis Co., Ltd. RS-2023-00259367
51 Development of small molecule targeting FoxM1 for the treatment of colorectal cancer
Small molecules Solid Cancer FoxM1 Lead Korea Research Institute of Chemical Technology(KRICT) RS-2023-00258901
52
Small molecules Solid Cancer TLS Lead D5 Therapeutics RS-2023-00258885
53 The generation of candidate for Relapsed and Refractory Acute Myeloid Leukemia to FLT3 inhibitors via direct STAT5/3 inhibition
Small molecules Acute Myeloid Leukemia STAT3/5 Candidate JW C&C Research Laboratories RS-2023-00258859
54 Development of a new Topoisomerase I inhibitor based on a Kamtotesin derivative that can be used as an ADC payload
Small molecules Solid Tumor Topoisomerase I Lead Pinotbio, Inc. RS-2023-00258783
55 Direct inhibitor of AR/AR.V7 DNA binding for castration.resistant prostate cancer
Small molecules Castration.resistant prostate cancer Androgen receptor (AR) and AR.V7 Candidate Incurix RS-2023-00258594
56 Lead optimization and candidate selection of PD.L1 small molecule inhibitor for non.clinical study
Small molecules Solid Cancer PD.1/PD.L1 Candidate Ilab RS-2023-00258167
57 Phase I Clinical Study of WM-S1-030 in patients with advanced or metastatic solid tumor
Small molecules Colorectal cancer mutant RON Phase 1 Wellmarkerbio Co., Ltd. RS-2023-00219060
58 Pre-clinical development of SCB0020160, a Sirt6 agonist with a potent anti-cancer effect
Small molecules pancreatic cancer SIRT6 Preclinical SCBIO RS-2023-00218894
59 Development of novel lead compounds inducing integrated stress response through HRI activation for the treatment of hematologic malignancies
Small molecules polycythemia vera HRI Lead NexThera Co., Ltd. RS-2023-00218778
60 Discovery of pre-clinical candidates for inhibition of SOS1 for the treatment of KRAS mutated cancers
Small molecules KRAS-mutated solid cancer(Pancreatic, Lung, Colon cancer) SOS1 Candidate Jeil Pharmaceutical RS-2023-00217674
61 Non-clinical studies of VRN101099, a brain permeable HER2 selective kinase inhibitor
Small molecules Breast cancer, Colon cancer HER2 Preclinical VORONOI RS-2023-00217541
62 Development of next-generation allosteric EGFR inhibitor for non-small cell lung cancer treatment
Small molecules NSCLC EGFR Candidate HK inno.N RS-2023-00217095
63 Structure based drug discovery of FOXM1 inhibitor for malignant tumor therapy
Small molecules Malignant tumor FOXM1 Hit Korea University College of Medicine RS-2022-00167112
64 A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Small molecules Solid Tumor TGFβR1 Phase 1 Tium BIO RS-2022-00167091
65 Discovery of STING allosteric activator targeting non-T cell inflamed tumor
Small molecules Solid Tumor STING Hit Korea Institute of Science and Technology RS-2022-00166522
66 Non-clinical Development of SREBP1 Degrader for the Cancer Stem Cell-targeted Treatment of Glioblastoma
Small molecules Glioblastoma SCAP:SREBP1 Preclinical MEDIFIC RS-2022-00166323
67 Development of 19S RP UCHL5 inhibitors for the treatment of relapsed and refractory multiple myeloma
Small molecules Multiple Myeloma 19S RP UCHL5 Lead Korea Research Institute of Bioscience and Biotechnology RS-2022-00166286
68 Discovery of novel PIP5K1a inhibitors as lead compounds for mCRPC therapy
Small molecules Prostate cancer PIP5K1α Lead TSD Life Sciences RS-2022-00165973
69 Non-clinical study on the development of customized targeted anticancer agent for the treatment of advanced Hepatocellular Carcinoma
Small molecules Liver cancer FLT3/VEGFR2/PDGFRb TK Preclinical Etnova Therapeutics RS-2022-00165725
70 Development of a novel HPK1/MLK3 dual inhibitor, an immuno-oncology agent for MLK3-specific solid tumors
Small molecules Brain cancer, Lung cancer HPK1/MLK3 Lead MD Biolab RS-2022-00165566
71 Development of **** inhibitor for immuno-metabolic modulator
Small molecules Colorectal cancer GCN2 Lead 1st Biotherapeutics, Inc RS-2022-00165544
72 Clinical Phase 1 Development of SKL27969, a Novel Brain Penetrating PRMT5 Inhibitor
Small molecules Glioblastoma PRMT5 Phase 1 SK Biopharmaceuticals RS-2022-00165541
73 Discovery of novel TTK (MPS1) inhibitors for the TNBC treatment
Small molecules TNBC TTK Lead Korea Research Institute of Chemical Technology HN22C0694
74 Anti-DX2 chemical drug to control KRAS-driven cancer
Small molecules Colorectal cancer (KRAS mutation) KRAS Candidate Zymedi HN22C0682
75 Non-clinical study of VRN11, a CNS-penetrable inhibitor for EGFR
G719X, L861X, S768I/V as well as C797S mutation NSCLC patients
Small molecules NSCLC(EGFR mutation) EGFR Preclinical Voronoi, Inc HN22C0663
76 Development of dual-functional hit/lead compounds targeting N3, a regulator of KRAS stability for the treatment of pancreatic cancer
Small molecules Pancreatic cancer NDRG3 Hit Korea Research Institute of Bioscience and Biotech HN22C0638
77 Discovery of Translocator Protein Targeting Cancer Therapeutics as effective substances
Small molecules Glioblastoma TSPO Hit Seoul National University HN22C0632
78 Preclinical study of DA-4505 for the treatment of cancer immunotherapy
Small molecules Advanced Solid Tumor AhR Preclinical DONG-A ST HN22C0630
79 JW2286, a novel inhibitor directly targeting of STAT3, drug discovery for solid cancer including triple negative cancer
Small molecules TNBC STAT3 Preclinical JW Pharmaceutical HN22C0583
80 ENPP1 Inhibitor TXN10128
Small molecules Colorectal cancer ENPP1 Preclinical TXINNO Bioscience Inc HN22C0531
81 Discovery and development of novel ULK1 inhibitor as a therapeutic drug for RAS-mutated cancers
Small molecules Colorectal cancer, Lung cancer, Pancreatic cancer ULK1 Lead TXINNO Bioscience Inc HN22C0244
82 Development of first-in class MASTL-targeted drug in triple-negative breast cancer
Small molecules Breast Cancer MASTL Lead Korea Institute of Radiological & Medical Sciences HN22C0173
83 Development of SHP2 allosteric inhibitor with dual mechanisms of targeting the RAS pathway and enhancing anti-tumor immunity
Small molecules Nsclc, Colerectal Cancer, Head and Neck Cancer, Esophageal Cancer SHP2 Candidate KANAPH Therapeutics HN22C0066
84 Discovery of novel nucleic acid-sensing pathway modulators for the TNBC treatment
Small molecules TNBC ENPP1 Hit Korea Institute of Science and Technology HN22C0063
85 Discovery of small molecular G9a inhibitor leads in advanced solid tumor: tumor growth inhibition and anti-cancer immunity activation
Small molecules Solid Tumor G9a Lead Asan Medical Center HN22C0033
86 A small molecule inhibitor of the ubiquitin activating enzyme for regulating p53 in lung cancer
Small molecules Lung cancer p53 or USE1 Lead Korea Research Institute of Chemical Technology HN21C1078
87 Non-clinical development of HM97662, an epigenetic protein EZH1/2 dual inhibitor, as a treatment for various cancers
Small molecules Malignant tumor EZH1/2 Preclinical Hanmi Pharm. Co., Ltd. HN21C1077
88 Identification of Preclinical Small Molecule Candidate which induces STING protein expression by inhibiting TRIM29-mediated STING Ubiquitination
Small molecules Solid Tumor TRIM29 Candidate SPARK Biopharma, Inc. HN21C1026
89 Pre-clinical Studies and IND Approval of First-in-class Cancer Stemness Blocking Anti-Cancer Agent, PMB212
Small molecules Resistant cancer PIN1 Preclinical PimedBio HN21C0955
90 Development of HMGCLL1 inhibitory small molecule CML therapeutic anticancer drug
Small molecules AML, CML HMGCLL1 Lead Samsung Medical Center HN21C0954
91 Discovery of lead compounds for the development of triple negative breast cancer treatments through HDAC6/8 dual inhibition
Small molecules TNBC HDAC6/8 Lead Sookmyung Women’s University HN21C0952
92 Preclinical study of JPC-089, a blood cancer treatment targeting PIM kinase
Small molecules AML PIM Kinase Preclinical Jeil Pharmaceutical CO.,LTD. HN21C0886
93 PhaseⅠclinical development of the 4th generation NSCLC-TKI BBT-176, which targets C797S-harboring EGFR mutations
Small molecules NSCLC EGFR(C797S) Phase 1 Bridge Biotherapeutics, Inc. HN21C0859
94 Discovery of drug candidate for HER2 positive Breast cancer treatment using HER2 targeted Small molecule with high brain permeability
Small molecules Breast cancer HER2 Candidate B2SBio Inc. HN21C0826
95 Novel Non-Covalent BTK Inhibitor, Exhibits Potent Anti-tumor Activity in B-Cell Lymphoma
Small molecules CML BTK (C481S) Candidate Medytox HN21C0823
96 Non-clinical study of VRN08, an oral Mps1 inhibitor to modulate SAC for advanced solid tumor
Small molecules TNBC and CDK4/6i resistant solid tumors Mps1 Preclinical Voronoi Inc. HN21C0580
97 Development of ***** Targeted New Drug Lead Compounds Activating IFN-γ for Immune Checkpoint Inhibitor Resistant Cancers
Small molecules Cancer TPST2 Hit GIST(Gwangju Institute of Science & Technology) HN21C0196
98 Development of a lead compound targeting USP21 for inhibiting cancer metastasis
Small molecules Colerectal cancer USP21 Lead Daegu Gyeongbuk Medical Innovation Foundation HN21C1210
99 Derivation of lead compound as TRIB2 inhibitor for development of triple negative breast cancer therapy
Small molecules Breast cancer TRIB2 Lead GENESEN Co., Ltd. HN21C1201
100 Lead identification of GLS1 target via allosteric inhibition
Small molecules Solid Tumor GLS1 Lead Korea Research Institute of Chemical Technology HN21C1180
BACK